Jefferies Reiterates Buy Rating on Aclaris Therapeutis (ACRS) Ahead of the Upcoming FDA Decisions on JAK Inhibitors in AD
Tweet Send to a Friend
Jefferies analyst Roger Song reiterated a Buy rating and $30.00 price target on Aclaris Therapeutis (NASDAQ: ACRS) as FDA reviews ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
